eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2023
vol. 48
 
Share:
Send email
Share:
abstract:
Case report

Newly diagnosed seropositive rheumatoid arthritis in a 52-year-old man superimposed on long-standing ankylosing spondylitis during secukinumab treatment

Jaroslaw Nowakowski
1
,
Anna Tomoń
2
,
Dorota Telesińska-Jasiówka
3
,
Mariusz Korkosz
1

  1. Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland
  2. Student’s Scientific Group of Rheumatology and Immunology, Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland
  3. University Hospital in Krakow, Krakow, Poland
Cent Eur J Immunol 2023; 48 (4): 346-349
DOI: https://doi.org/10.5114/ceji.2023.132066
Online publish date: 2023/10/13
View full text Get citation
 
PlumX metrics:
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are severe chronic inflammatory joint diseases with different immune-mediated mechanisms playing a role in their pathogenesis. Rheumatoid arthritis is an erosive arthritis of peripheral joints and AS is a spondyloarthropathy affecting mainly sacroiliac and spinal joints leading to excessive bone formation and ankylosis. The coexistence of RA and AS in the same patient is rare. Presented here is a 52-year-old patient with long-standing AS with bilateral ankylosis of sacroiliac joints who developed peripheral symmetric polyarthritis while being treated with the interleukin 17 inhibitor secukinumab introduced due to secondary inefficacy of the tumor necrosis a inhibitor etanercept. He was finally diagnosed with seropositive RA coexisting with AS and treatment was changed to the Janus kinase inhibitor tofacitinib. Eventually, remission was sustained with use of the interleukin 6 inhibitor tocilizumab. This is the first case of RA developing during anti-interleukin 17 therapy. Although tocilizumab lacks efficaciousness in AS, in this case therapy was succesful as the RA-driving cytokine mechanism possibly prevailed.
keywords:

biologics, arthritis, spondylitis, rheumatoid, ankylosing
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.